KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.

Lingying Wu, Jing Wang, Qingshui Li, Danbo Wang, Cuiying Zhang, Junying Tang, Guonan Zhang, Min Hao, Desheng Yao, Qinglei Gao, Youzhong Zhang, Ruifang An, Rutie Yin, Li Wang, Bairong Xia, Qi Zhou, Hongying Yang, Jianqing Zhu, Kui Jiang, Zhengzheng Chen, Qiang Wu, Wei Duan, Yi Huang, Hui Zhang, Shuqing Wei, Guiling Li, Yuanguang Meng, Ke Wang, Xinfeng Yang, Xianghua Huang, Lingya Pan, Jinjin Yu, Ge Lou, Yu Zhang, Huaijun Zhou, Xiaoqing Guo, Hong Yang, Xiaodong Cheng, Xiumin Li, Wuliang Wang, Hongqin Zhao, Yunxia Li, Yingjie Yang, An Lin, Wenjun Cheng, Lihong Chen, Xiaoying Xie, Wen Di, Yuanjing Hu, Mo Chen, Hongwu Wen, Liping Cai, Xiaohua Wu, Zhongqiu Lin, Quanren Wang, Xinfeng Yang, Ning Li

CA Cancer J Clin 76(1) e70042

PMID41287969
PMCIDPMC12645347
DOI10.3322/caac.70042
发表日期2025-11-25
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

Although poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPis) and bevacizumab were approved as first-line maintenance for advanced ovarian cancer (OC), evidence comparing this combination with PARPi monotherapy, especially in BRCA-mutated/homologous recombination-deficient (HRD) patients, is lacking. This study compared combined fuzuloparib (a PARPi) plus apatinib (a vascular endothelial growth factor receptor-2 inhibitor) with either fuzuloparib or placebo as first-line maintenance in patients with advanced OC. Patients who had newly diagnosed, advanced OC and responded to first-line, platinum-based chemotherapy were randomized 2:2:1 to receive combined fuzuloparib (100 mg twice daily) plus apatinib (375 mg daily), fuzuloparib (150 mg twice daily) plus placebo, or double-placebo treatment. The primary end point was blinded independent review committee (BIRC)-assessed progression-free survival (PFS). Six hundred seventy-four patients were randomized to receive fuzuloparib plus apatinib (n = 269), fuzuloparib (n = 269), or placebo (n = 136). At the final analysis (November 1, 2024; 385 BIRC-assessed PFS events; median follow-up, 40 months), the median BIRC-assessed PFS was 26.9 months with the combination versus placebo (hazard ratio [HR], 0.57; 95% confidence interval [CI], 0.44-0.75; one-sided p < .0001) and 29.9 months with fuzuloparib monotherapy versus placebo (HR, 0.58; 95% CI, 0.44-0.75; one-sided p < .0001) compared with 11.1 months with placebo. A PFS benefit was observed regardless of germline BRCA1/2 mutation status. In homologous recombination-deficient patients (including those with BRCA1/2 mutations), combined fuzuloparib and apatinib produced a PFS similar to that of fuzuloparib (34.1 vs. 35.8 months, respectively); in homologous recombination-proficient patients, PFS had a trend favoring the combination (16.6 vs. 11.0 months; HR, 0.73; 95% CI, 0.45-1.19). Both treatments were well tolerated. Overall survival was immature. Both fuzuloparib and combination therapy improved PFS compared with placebo as maintenance therapy for patients who had newly diagnosed, advanced OC. Adding apatinib to fuzuloparib did not prolong PFS among homologous recombination-deficient patients. There was a PFS benefit trend among homologous recombination-proficient patients who received combination therapy compared with those who received monotherapy.

KM 提取结果

3 个 Figure · 5 个 KM 面板

进入结果中心
KM Figure1 个面板

FIGURE 1

FIGURE 1 Progression‐free survival assessed by a blinded independent review committee in the overall population. Tick marks indicate the time points at which data were censored. CI indicates confidence interval; HR, hazard ratio; PFS, progression‐free survival.

Figure_1

PFS

FIGURE 1 · Panel Figure_1

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel Figure_1 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 1:short span曲线 3:extreme upward reversal
查看结果
KM Figure2 个面板

FIGURE 2

FIGURE 2 Progression‐free survival assessed by a blinded independent review committee in (A) the germline BRCA1/2 ‐mutated subpopulation and (B) the germline BRCA1/2 wild‐type subpopulation. Tick marks indicate the time points at which data were censored. CI indicates confidence interval; HR, hazard ratio; NR, not reached; PFS, progression‐free survival.

A

PFS

FIGURE 2 · Panel A

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel A 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal曲线 3:off origin start
查看结果
B

PFS

FIGURE 2 · Panel B

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel B 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 3 条,实际恢复 2 条曲线 2:extreme jump曲线 2:extreme upward reversal曲线 3:extreme jump
查看结果
KM Figure2 个面板

FIGURE 3

FIGURE 3 Progression‐free survival assessed by a blinded independent review committee in (A) the HRD subgroup and (B) the HRP subgroup. Tick marks indicate the time points at which data were censored. CI indicates confidence interval; HR, hazard ratio; HRD, homologous recombination deficiency; HRP, homologous recombination proficient; NR, not reached; PFS, progression‐free survival.

A

PFS

FIGURE 3 · Panel A

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel A 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 1:extreme upward reversal曲线 2:extreme upward reversal
查看结果
B

PFS

FIGURE 3 · Panel B

quality_warning 待 EXE 对齐 预期 3 条 已提取 1 条

Panel B 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 3 条,实际恢复 1 条曲线 1:off origin start曲线 1:extreme upward reversal曲线 2:extreme jump
查看结果